MDxHealth (NASDAQ:MDXH) reported first-quarter 2026 revenue of $27.4 million while announcing a strategic exit from its Resolve UTI testing business and the planned closure of its Plano, Texas, laboratory facility, a move executives said will sharpen the company’s focus on prostate cancer diagnostic
After months of work, we’re proud to release the Master Swing Trading Course - a 175-page deep dive designed from your feedback and our three decades of market experience.
